Chamber and committees

According to Rape Crisis Scotland, as of October 2020 and December 2021 waiting list times for each centre were as follows:

The A92 A96 Haudagain Improvement project, which was anticipated to be complete in winter 2021, has faced a number of challenges including the impact of the pandemic continuing to disrupt progress. The contractor has indicated a revised date for completing the works, with the Improvement now due to open to traffic by the end of March 2022 as detailed in the recent press release available on the Transport Scotland website at:  https://www.transport.gov.scot/news/a92a96-haudagain-improvement-update-to-expected-completion-date/ .

I also refer the member to the answer to question S6W-05362 on 21 December 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .

The Learning Estate Investment Programme has made significant progress since the first projects were announced in September 2019, with projects in construction and in development representing a £1.2bn investment in the learning estate.

The Scottish Government intend to announce the projects that will form part of Phase 3 of the programme within the next 12 months. We will write to local authorities seeking investment proposals in 2022 and in the meantime we will work with local government to agree the development programme timeline.

I refer the member to the answer to question S6W-05057 on 23 December 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

Proof of COVID-19 booster vaccination will appear on the NHS Scotland Covid Status app within 24 hours of the vaccine being administered.

The Scottish Government continues to closely monitor all emerging evidence on the effectiveness of COVID-19 treatments and their clinical effectiveness. The Medicines and Healthcare products Regulatory Agency (MHRA) is now assessing Paxlovid’s safety and effectiveness, and I cautiously welcome analysis of the final clinical trial results from Pfizer (which are yet to be published or verified) which show that Paxlovid cuts the risk of hospitalisation or death by approximately 89% in high risk, non-hospitalised adult patients with mild-to-moderate COVID-19. If approved by the MHRA, this will represent another significant pharmaceutical option in our response to COVID-19.

On 20th October, the UK Government announced that 250,000 treatment courses of Paxlovid had been ordered, pending regulatory approval. On 22nd December, the UK Government announced that a further 2.5 million treatment courses had been ordered as part of efforts to reduce the impact of COVID-19 and the Omicron variant across the UK. If authorised by the MHRA, the intention is to initially deploy antivirals such as Paxlovid to individuals through a UK-wide national study, funded by the National Institute for Health Research (NIHR). The University of Oxford has been selected to lead the study . This will enable collection of additional data to address limitations in the company-sponsored trials, for example the effectiveness of the treatments in vaccinated patients, as participants in the company trials were unvaccinated.

In developing proposals for the regulation of short-term lets, the Scottish Government has conducted three public consultations. Our most recent consultation closed on 13 August 2021, and we received 1,026 responses.

We carefully considered suggestions for changes to the legislation from working group members, and stakeholders responding to our third consultation, including the Association of Scotland’s Self-Caterers. The changes set out in the consultation report align with the policy objectives of ensuring all short-term lets comply with basic safety requirements, without undermining protections for guests, neighbours and local communities. These include significant and pragmatic changes in response to concerns from the tourism sector, such as the removal of overprovision and stronger guidance on fees.

At the heart of our licensing scheme is a set of mandatory standards which will help to protect the safety of guests and neighbours in short-term lets across Scotland. Provided an operator continues to comply with their licence conditions, which will often just be the mandatory safety conditions, their licence would normally be renewed. As the licensing scheme requires licence holders to comply with mandatory safety conditions, and they cannot continue to operate if they do not, it is reasonable to assume that lenders will have regard to this as part of their due diligence, alongside other considerations such as turnover and profitability.

Data published by Public Health Scotland covering the period 01 January 2020 to 30 September 2021 shows that in NHS Grampian 83.7 % eligible referrals started treatment within the 62 day standard in 2020 and 78.2% in 2021. Representing 1081 of 1,291 referrals in 2020 and 815 of 1,042 referrals in 2021.

Further breakdown of this data can be accessed at Cancer waiting times - 1 July to 30 September 2021 - Cancer waiting times - Publications - Public Health Scotland .

Boards are continuing to prioritise new cancer patients being referred with a suspicion of cancer - this is closely monitored through weekly performance meetings with officials and reflected in Boards’ Remobilisation Plans.

A refresh of the Framework for Effective Cancer Management is underway and will support clinicians and NHS managers to drive improvements in cancer pathways, providing Health Boards with the tools to effectively manage cancer patients and ultimately recover waiting times.

£10 million of funding has been directed to support cancer waiting times improvements in NHS Scotland across 2021-22, including up-skilling nurses and investing in diagnostic tests to extended working days and weekend working, to increase capacity and see/treat cancer patients as timely as possible. NHS Grampian received £974,000 as a share of the funding.

Prioritisation within the Scottish Government’s COVID-19 vaccination programme is based upon the clinical risk of developing severe disease with COVID-19. The Joint Committee on Vaccination and Immunisation (JCVI) advises on clinical prioritisation for vaccination. Priority groups 1-9 incorporate the highest clinical risk groups and each group cohort is invited to receive vaccination accordingly.

As per guidance outlined within the Green Book, Chapter 14a, children and young people aged 12-15 years with poorly controlled asthma that requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission, are included as a high risk group within chronic respiratory disease.

For full details please see p19-23: COVID-19: the green book, chapter 14a - GOV.UK (www.gov.uk) .